Fig. 2

3,6-DHF promotes the expression of TET1 during carcinogens-induced breast carcinogenesis. a Western blots showing levels of TET1 in the cellular breast carcinogenesis model. b The level of TET1 in breast tissues (0, 2 w) and tumors (18 w) in MNU-treated rats with 3,6-DHF administration (20 mg/kg, i.g.), as detected by immunohistochemistry and western blot c Immunohistochemistry of TET1 in xenografted breast tumors in breast tumors in athymic mice. d Western blos showing levels of TET1 in breast tissues (0, 2 w) and tumors (18 w) in MNU-treated rats, and in xenografted breast tumors in athymic mice. Immunostaining density was quantified using image J analysis. The data are presented as the mean ± SD (n = 3).^* P < 0.05, ^** P < 0.01 compared with control. ^# P < 0.05 compared with 0 W